[PDF] Top 20 Biosimilar medicines and cost-effectiveness

... the biosimilar and the reference bio- pharmaceutical in terms of duration of severe neutropenia was supported by one randomized controlled trial in breast cancer ...the biosimilar in general. The ... See full document

... [13] cost data on scheduled healthcare visits to their usual physician and specialist, unscheduled health- care asthma related in-patient admissions, emergency visits, and emergency contacts with a ...The ... See full document

... drugs’ effectiveness and safety should be established with the chance for profession- als to give feedback; and finally, financial and nonfinancial incentives could be useful to align the system’s and the ... See full document

... supplying medicines in existing ...for medicines management (stock books, stock cards, borrow and lend records, expired medicines registers, EMHS list, EMHS manual, clinical guidelines, tablet ... See full document

... a biosimilar who had previously received a biooriginator felt that their medication was too expensive compared with the other patient groups, yet more of this group was concerned that they were being given a ... See full document

... the cost of chemotherapy-induced anaemia among originator epoetin α, epoetin β and darbepoetin α and biosimilar epoetin α at the level of a single patient using various dosing ...single biosimilar ... See full document

... (Scottish Medicines Consortium, 2011). Biosimilar GCSF is found to be equally efficacious and safe without affecting patient out- comes (Aapro et ...2014). Biosimilar Zarzio can be safely used in the ... See full document

... treatment cost varies depending on the medicines used, like, a comparatively cheaper Disease Modifying Anti Rheumatic Drug (DMARD) or a costlier biological ...was cost effectiveness analysis ... See full document

... a cost-efficient treatment strategy for the Italian and Spanish health services compared to the biosimilar in the treatment of infertility and require further investigation for the other ...of ... See full document

... provided. Cost-saving and reinvestment opportunities should be identified, and gain-share agreements explored (arrangement between healthcare commissioners and providers to share the benefits associated with more ... See full document

... Biological medicines are starting to lose their patent protection, so similar, inexact copies (biosimilars) are being developed and ...preferred medicines for prescribing in local healthcare ... See full document

... for biosimilar mAbs were issued by the EMA determining that biological activity should be characterized by a comparabil- ity study using sensitive immunological methods able to detect differences between a ... See full document

... Roflumilast has been shown to be effective in improving lung function and decreasing COPD exacerbations which are typically associated with the vulnerable patient popula- tion. However, it is important to consider both ... See full document

... complete cost and QALY data had better pain ...be cost-effective at current NICE recommended thresh- olds, even if complete cost and QALY data had been ... See full document

... the cost-effectiveness of disease-modifying drugs (DMDs), such as interferons and glatiramer acetate, with more up to date therapies, such as mitaxantrone hydrochloride and natalizumab in the treatment of ... See full document

... interpreting cost-effectiveness studies to ensure that all underlying assumptions have been made explicit and the context and perspective of the study are adequately ...All cost-effectiveness ... See full document

... Background: Primary total knee replacement is a common operation that is performed to provide pain relief and restore functional ability. Inpatient physiotherapy is routinely provided after surgery to enhance recovery ... See full document

... Most economic studies on cervical screening published in the last decade appear to have focussed on HPV testing, which was outside the scope of this study. Therefore, the literature search was extended to encompass the ... See full document

... The cost of treatment includes not only direct costs but also indirect ...in cost-effectiveness and cost-utility analysis studies of medical interventions like chemotherapy for cancer ... See full document

... Vaso-occlusive crises (VOC) due to tissue ischemia are one of the most common acute manifestations of the disease and the leading cause of hospitalization (Girot, 2007; Fosdal, 2007). The average cost for the ... See full document